A5077300810- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Genetic factors in colorectal cancer
- Esophageal Cancer Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Circular RNAs in diseases
- Colorectal and Anal Carcinomas
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Metastasis and carcinoma case studies
- Lymphoma Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Fibroblast Growth Factor Research
- Renal cell carcinoma treatment
- Monoclonal and Polyclonal Antibodies Research
- Colorectal Cancer Surgical Treatments
- Cancer Research and Treatments
Royal Marsden Hospital
2014-2024
Royal Marsden NHS Foundation Trust
2014-2023
University Medical Center Groningen
2019
University of Groningen
2019
Assistance Publique – Hôpitaux de Paris
2019
Université Paris Cité
2019
Hôpital Beaujon
2019
National Health Service
2009-2016
Samsung Medical Center
2015
New Cross Hospital
2015
Cancer organoids to model therapy response are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches used predict drug responses clinic. They generated a live organoid biobank patients with metastatic gastrointestinal cancer who had previously been enrolled phase I or II clinical trials. This allowed authors compare how actually responded Encouragingly,...
FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition cancers is unknown. In a translational clinical trial, we show that gastric with high-level clonal amplification have high rate the selective inhibitor AZD4547, whereas subclonal or low-level did not respond. Using cell lines patient-derived xenograft models, initiates distinct oncogene addiction phenotype, characterized by FGFR2-mediated transactivation of alternative receptor kinases,...
Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis resistance landscape in 35 RAS wild-type CRCs identified associations NF1 non-canonical RAS/RAF aberrations with primary validated CRC subtypes as non-genetic predictors benefit. Sixty-four percent biopsies acquired harbored no genetic drivers. Most these had switched from cetuximab-sensitive subtype at baseline to...
Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection patient progression. However, how to exploit the predictive power cfDNA as a liquid biopsy in clinic remains unclear. RAS pathway aberrations can be tracked monitor resistance anti-EGFR monoclonal antibodies patients with metastatic colorectal cancer. In this prospective phase II clinical trial single-agent cetuximab
Recruitment to clinical trials can be challenging and slower than anticipated. This prospective patient survey aimed investigate the proportion of patients approached about a trial who agree participate, their motivations for participation views on aspects cancer research.Patients had been in any Gastrointestinal Lymphoma Unit at Royal Marsden were invited complete questionnaire. The statistical analysis is mainly descriptive, with percentages being reported. Univariate logistic regression...
<h3>Background</h3> Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomics investigate neoantigen presentation whether this augmented through interferon gamma (IFNγ) or MEK-inhibitor treatment. <h3>Methods</h3> Four microsatellite stable PDOs chemotherapy refractory one a treatment naïve CRC were expanded replicates with 100 million...
Response to preoperative chemo-radiotherapy (CRT) varies. We assessed whether circulating tumor DNA (ctDNA) might be an early indicator of response or progression guide therapy adaptation in rectal cancer.
<h3>Background</h3> The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 cells, which triggers killing of lines expressing moderate to high levels CEA at the surface. Patient derived colorectal organoids (PDOs) may more accurately represent patient tumors than established potentially enables detailed insights into mechanisms resistance sensitivity. <h3>Methods</h3> We PDOs from multidrug-resistant metastatic CRCs. expression was...
Abstract Purpose: The multi-kinase inhibitor (mKi) regorafenib has demonstrated efficacy in chemorefractory patients with metastatic colorectal cancer (mCRC). However, lack of predictive biomarkers and concerns over significant toxicities hamper the use clinical practice. Experimental Design: Serial liquid biopsies were obtained at baseline monthly until disease progression mCRC treated a phase II trial (PROSPECT-R n = 40; NCT03010722) multicentric validation cohort (n 241). Tissue collected...
Insulin-like growth factor type 1 receptor (IGF-1R) mediates resistance to epidermal (EGFR) inhibition and may represent a therapeutic target. We conducted multicenter, randomized, double blind, phase II/III trial of dalotuzumab, an anti-IGF-1R monoclonal antibody, with standard therapy in chemo-refractory, KRAS wild-type metastatic colorectal cancer. Eligible patients were randomly assigned dalotuzumab 10mg/kg weekly (arm A), 7.5mg/kg every alternate week B), or placebo C) combination...
Objective Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection. Design Patients RAS mutant mCRC biopsiable metastases were enrolled this phase II trial. Dynamic contrast-enhanced (DCE) MRI was acquired pretreatment at day 15 post-treatment. Median values volume transfer constant (K trans ), enhancing fraction (EF) their...
Abstract BACKGROUND Circulating free DNA sequencing (cfDNA-Seq) can portray cancer genome landscapes, but highly sensitive and specific technologies are necessary to accurately detect mutations with often low variant frequencies. METHODS We developed a customizable hybrid-capture cfDNA-Seq technology using off-the-shelf molecular barcodes novel duplex molecule identification tool for enhanced error correction. RESULTS Modeling based on cfDNA yields from 58 patients showed that this...
Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions recommended. We conducted retrospective study to evaluate impact implementing variant testing for patients gastrointestinal cancers routine clinical practice high volume cancer centre London, United Kingdom.Patients receiving chemotherapy prior to, following implementation were identified...
PURPOSE: The purpose of this study was to assess the longitudinal impact stoma formation on health-related quality life rectal cancer patients treated with adjuvant chemotherapy. METHODS: Health-related data prospectively collected in a randomized trial designed compare 24 weeks bolus 5-fluorouracil/leucovorin 12 continuous 5-fluorouracil resected Dukes B and C colorectal cancer. at baseline, during treatment, one three years after completion RESULTS: Between 1993 2003, 186 were enrolled....
SBA is a rare tumour which carries poor prognosis. Very few data on prognostic factors and treatment outcomes are available. We conducted retrospective analysis of patients treated for at our institution.Clinico-pathological characteristics, treatments all the consecutively from 1996 to 2011 were retrospectively collected. The value baseline was assessed using Cox regression model. Kaplan-Meier method used estimate survival outcomes.Eighty-four with during study period. Of these, 48...
// Khurum Khan 1 , David Cunningham Clare Peckitt Sarah Barton Diana Tait Maria Hawkins 1,2 Watkins Naureen Starling Sheela Rao Ruwaida Begum Janet Thomas Jacqui Oates Vincenza Guzzardo 3 Matteo Fassan Chiara Braconi 1,4 and Ian Chau Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK 2 CRUK/MRC Oxford Institute for Radiation Oncology, Gray Laboratories, University of Oxford, Department Medicine, Padua, IT 4 Division Cancer Therapeutics, Research, Correspondence to:...
2508 Background: FGFR1/2 amplification acts as an oncogenic driver in multiple cancers. We investigated the efficacy of AZD4547, a potent orally available selective inhibitor FGFR 1,2 & 3 receptor tyrosine kinases, amplified Methods: This is phase II Simon 2 stage design for patients (pts) with FGFR1 (HER2 negative breast/NSCLC) or FGFR2 (gastroesophageal) tumors treated AZD4547 80mg twice daily on intermittent (2 weeks (wks) on, 1 wk off) continuous schedule. Eligible pts had progressed...